ENDRA Life Sciences Past Earnings Performance
Past criteria checks 0/6
ENDRA Life Sciences has been growing earnings at an average annual rate of 1.9%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 109% per year.
Key information
1.9%
Earnings growth rate
53.6%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | -109.0% |
Return on equity | -177.8% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks
Sep 29ENDRA Life Sciences receives European patent for TAEUS system
Aug 24Endra Life Sciences Q2 2022 Earnings Preview
Aug 12We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Aug 08We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Nov 18We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully
Jul 19ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer
Jun 15ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology
Jan 13ENDRA Life Sciences renews GE Healthcare collaboration agreement
Dec 21Endra Life prices $5M-share offering
Dec 16Endra Life Sciences EPS beats by $0.02
Nov 16Revenue & Expenses BreakdownBeta
How ENDRA Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -10 | 6 | 5 |
30 Sep 23 | 0 | -12 | 6 | 6 |
30 Jun 23 | 0 | -12 | 6 | 6 |
31 Mar 23 | 0 | -13 | 7 | 7 |
31 Dec 22 | 0 | -13 | 7 | 7 |
30 Sep 22 | 0 | -13 | 7 | 6 |
30 Jun 22 | 0 | -12 | 6 | 6 |
31 Mar 22 | 0 | -12 | 6 | 6 |
31 Dec 21 | 0 | -11 | 6 | 5 |
30 Sep 21 | 0 | -10 | 5 | 5 |
30 Jun 21 | 0 | -11 | 5 | 6 |
31 Mar 21 | 0 | -11 | 5 | 6 |
31 Dec 20 | 0 | -12 | 6 | 6 |
30 Sep 20 | 0 | -19 | 6 | 7 |
30 Jun 20 | 0 | -19 | 5 | 7 |
31 Mar 20 | 0 | -18 | 5 | 6 |
31 Dec 19 | 0 | -18 | 4 | 7 |
30 Sep 19 | 0 | -11 | 4 | 6 |
30 Jun 19 | 0 | -10 | 4 | 5 |
31 Mar 19 | 0 | -10 | 4 | 5 |
31 Dec 18 | 0 | -10 | 4 | 5 |
30 Sep 18 | 0 | -10 | 4 | 5 |
30 Jun 18 | 0 | -8 | 4 | 4 |
31 Mar 18 | 0 | -7 | 4 | 4 |
31 Dec 17 | 0 | -5 | 3 | 2 |
30 Sep 17 | 1 | -4 | 2 | 1 |
30 Jun 17 | 1 | -4 | 2 | 1 |
31 Mar 17 | 1 | -3 | 2 | 0 |
31 Dec 16 | 1 | -3 | 2 | 0 |
30 Sep 16 | 0 | -3 | 1 | 1 |
30 Jun 16 | 1 | -2 | 1 | 1 |
31 Mar 16 | 1 | -2 | 1 | 1 |
31 Dec 15 | 1 | -2 | 1 | 1 |
31 Dec 14 | 1 | -2 | 1 | 1 |
Quality Earnings: NDRA is currently unprofitable.
Growing Profit Margin: NDRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NDRA is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.
Accelerating Growth: Unable to compare NDRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NDRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.3%).
Return on Equity
High ROE: NDRA has a negative Return on Equity (-177.77%), as it is currently unprofitable.